SSR4: A Protein Involved in Disease and Drug Development (G6748)

Target Name: SSR4

NCBI ID: G6748

SSR4

SSR4: A Protein Involved in Disease and Drug Development

SSR4 (Translocon-Associated Protein (TRAP) Complex) is a protein that is expressed in various tissues of the body, including the brain, spleen, and peripheral tissues. It is a member of the superfamily of ATP-binding proteins, which are characterized by the presence of an ATP-binding domain in the protein sequence.

One of the unique features of SSR4 is its ability to form a complex with other proteins, including the protein translocon, which is a protein that is involved in the transfer of DNA from the cytoplasm to the nucleus. This complex formation is important for the regulation of gene expression and the function of the immune system.

SSR4 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes is thought to be due to its ability to interact with other proteins and to regulate the activity of cellular signaling pathways.

In addition to its role in disease, SSR4 has also been identified as a potential drug target. Its unique structure and the fact that it can form a complex with translocon make it an attractive target for small molecule inhibitors. Currently, there are several SSR4-based drugs in development, which are aimed at inhibiting its activity and at treating various diseases.

One of the most promising compounds that is being developed as an SSR4 inhibitor is N-Acetyl-L-Tyr(297). This compound is a peptide that binds to the TRAP protein and inhibits its activity. N-Acetyl-L-Tyr(297) has been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another compound that is being developed as an SSR4 inhibitor is 2-Mercaptoethanesulfonic acid (2-MES), which is a compound that inhibits the activity of the TRAP protein and its ability to form the complex with translocon. 2-MES has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, SSR4 is a protein that plays a critical role in the regulation of gene expression and the immune system. Its ability to form a complex with other proteins, including translocon, makes it an attractive target for small molecule inhibitors. Currently, several SSR4-based drugs are in development, including N-Acetyl-L-Tyr(297) and 2-Mercaptoethanesulfonic acid, which are aimed at treating various diseases. Further research is needed to fully understand the role of SSR4 in disease and to develop safe and effective treatments.

Protein Name: Signal Sequence Receptor Subunit 4

Functions: TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins

The "SSR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets